As Figure 3B demonstrates, we screened out the top four keywords whose citation bursts continued to 2022, including “benralizumab”, “severe asthma”, “blood eosinophil count”, “omalizumab”, “rhinosinusitis”, “oral corticosteroid”, “thymic stromal lymphopoietin”, and “guideline”. This evidence concerns the gene TSLP and common cold.